Optimizing Retention Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Brief description of study

This multicenter study seeks to better evaluate treatment strategies for the management of opioid use disorder – it aims to improve treatment outcomes for both patients starting medication for opioid use disorder (MOUD) (Retention Phase) and those wishing to discontinue MOUD (Discontinuation Phase). The purpose of the Retention Phase is to test strategies, including medications, to help patients with opioid use disorder stay in treatment. Patients seeking treatment for OUD will choose either buprenorphine (BUP) or extended-release naltrexone (XR-NTX). Participation in the study will last about two years. The purpose of the Discontinuation Phase is to test approaches to improve outcomes of patients who are stable on MOUD and are seeking to discontinue their medication. Participants will not be actively recruited; instead, eligible patients on BUP or XR-NTX will be referred to the study by their provider. Participants have up to 48 weeks to complete their medication taper. In both phases, participants will be randomized to receive Medical Management (MM) alone, or MM plus a technology-based behavioral phone application.

Clinical Study Identifier: s20-00773
Principal Investigator: Mathew B. Kladney.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.